Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio Key International (BKYI) EBITDA (2016 - 2025)

Bio Key International's EBITDA history spans 16 years, with the latest figure at -$1.0 million for Q3 2025.

  • For Q3 2025, EBITDA fell 60.17% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached -$4.3 million, up 15.92%, while the annual FY2024 figure was -$4.3 million, 48.23% up from the prior year.
  • EBITDA for Q3 2025 was -$1.0 million at Bio Key International, up from -$1.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$572560.0 in Q1 2024 and bottomed at -$6.8 million in Q4 2022.
  • The 5-year median for EBITDA is -$1.4 million (2024), against an average of -$1.7 million.
  • The largest annual shift saw EBITDA plummeted 478.25% in 2021 before it surged 67.15% in 2023.
  • A 5-year view of EBITDA shows it stood at -$2.0 million in 2021, then plummeted by 240.23% to -$6.8 million in 2022, then soared by 67.15% to -$2.2 million in 2023, then surged by 36.91% to -$1.4 million in 2024, then increased by 26.32% to -$1.0 million in 2025.
  • Per Business Quant, the three most recent readings for BKYI's EBITDA are -$1.0 million (Q3 2025), -$1.1 million (Q2 2025), and -$729742.0 (Q1 2025).